HC Wainwright Issues Optimistic Forecast for Harrow Earnings

Harrow, Inc. (NASDAQ:HROW) – Equities research analysts at HC Wainwright upped their Q4 2024 earnings per share (EPS) estimates for shares of Harrow in a report issued on Tuesday, March 18th. HC Wainwright analyst Y. Chen now forecasts that the company will earn $0.16 per share for the quarter, up from their prior forecast of ($0.07). HC Wainwright has a “Buy” rating and a $57.00 price objective on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.07 EPS and FY2025 earnings at $0.21 EPS.

Separately, B. Riley decreased their price target on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th.

Harrow Stock Up 1.1 %

NASDAQ HROW opened at $28.41 on Friday. The stock has a market cap of $1.01 billion, a PE ratio of -30.22 and a beta of 0.69. Harrow has a fifty-two week low of $9.86 and a fifty-two week high of $59.23. The business has a 50 day moving average price of $29.51 and a two-hundred day moving average price of $38.39. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Institutional Trading of Harrow

A number of hedge funds have recently made changes to their positions in HROW. GF Fund Management CO. LTD. acquired a new stake in shares of Harrow during the fourth quarter worth approximately $25,000. Quest Partners LLC acquired a new position in Harrow in the third quarter worth $29,000. Tower Research Capital LLC TRC boosted its holdings in Harrow by 769.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock worth $55,000 after purchasing an additional 1,462 shares during the period. Aquatic Capital Management LLC acquired a new position in Harrow in the fourth quarter worth $78,000. Finally, AlphaQuest LLC boosted its holdings in Harrow by 452.8% in the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock worth $118,000 after purchasing an additional 2,889 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.